(Q42619498)

English

Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial

scientific article published on 9 February 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

Carolyn A. Young

11

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Paola Valsasina

object named as

P Valsasina

4

0 references

Massimo Filippi

object named as

M Filippi

10

0 references

1

object named as

M Rovaris

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

author name string

G Comi

2

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

M A Rocca

3

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

D Ladkani

5

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

E Pieri

6

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

S Weiss

7

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

G Shifroni

8

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

J S Wolinsky

9

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

publication date

9 February 2007

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

502-508

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Glatiramer acetate in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070704

21 January 2018

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070704

21 January 2018

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070704

21 January 2018

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070704

21 January 2018

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070704

21 January 2018

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070704

21 January 2018

Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070704

21 January 2018

Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070704

21 January 2018

Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070704

21 January 2018

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070704

21 January 2018

Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070704

21 January 2018

Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070704

21 January 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070704

21 January 2018

Normalized accurate measurement of longitudinal brain change.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070704

21 January 2018

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070704

21 January 2018

Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070704

21 January 2018

Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone).

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070704

21 January 2018

Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070704

21 January 2018

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070704

21 January 2018

Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070704

21 January 2018

The relation between MRI measures of inflammation and neurodegeneration in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070704

21 January 2018

The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070704

21 January 2018

Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070704

21 January 2018

Identifiers

10.1177/1352458506070704

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42619498&oldid=1963265277"